TuesdayDec 17, 2024 2:58 pm

CBDNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Closes $3.6M Registered Direct

Flora (NASDAQ: FLGC) has closed a registered direct offering to institutional investors for the aggregate purchase and sale of approximately $3.6 million of Common Shares, each at a price of $1.25. Flora announced approximately $3.6 million in expected aggregate gross proceeds from the offering, of which it intends to use the net, together with existing cash, for general corporate purposes and working capital. Aegis Capital Corp. acted as exclusive placement agent for the offering. Dorsey & Whitney LLP acted as counsel to the company, and Kaufman & Canoles P.C. acted as counsel to Aegis Capital Corp. To view the full…

Continue Reading

ThursdayNov 21, 2024 11:30 am

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) to Host Spaces Event, Share Comprehensive Update on Destino Ranch

Golden Triangle Ventures (OTC: GTVH) (“GTV”) today announced its plans to host a Spaces call at 1:30 p.m. PST on Wednesday, Dec. 11, 2024, on the company’s official X account, @GTV_Inc. Steffan Dalsgaard, president of Golden Triangle Ventures and CEO of Lavish Entertainment, alongside Marco Moreno, president of Lavish Entertainment, will lead the event and deliver a comprehensive update on the company’s transformative flagship project — Destino Ranch. GTV’s wholly owned subsidiary Lavish Entertainment is spearheading the development of Destino Ranch, which is poised to become a world-renowned destination and premier experiential hospitality and entertainment venue, including immersive art installations,…

Continue Reading

ThursdayOct 24, 2024 12:45 pm

CBDNewsBreaks – CBD Life Sciences Inc. (CBDL) Poised to Become Game Changer in the Hemp Industry

CBD Life Sciences (OTC: CBDL) today announced its potential for explosive profits in a $70 billion industry and, with its innovative product line and strategic market positioning, standing ready to deliver unparalleled returns for shareholders. “The U.S. is on the verge of a historic shift. With the Biden administration, led by Vice President Kamala Harris, taking bold steps toward federal marijuana legalization, the opportunities for companies in the cannabis and CBD sectors are poised to skyrocket,” the announcement reads. “According to industry projections, the legal cannabis market in the U.S. is expected to surpass $70 billion by 2028, driven by…

Continue Reading

WednesdayOct 16, 2024 12:20 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Subsidiary Negotiating Pharma Cannabis Supply Deal with Australian Firm

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, today announced that its Colombian subsidiary is in negotiations with an Australian pharmaceutical company to supply medical-grade cannabis. The agreement is expected to generate between $100,000 and $200,000 in monthly revenue once operations begin. MedCana's CEO, Jose Gabriel Diaz, emphasized the significance of this deal in the company’s ongoing global expansion aimed at meeting the rising demand for high-quality cannabis products. To view the full press release, visit https://cnw.fm/uIXJh About Software Effective Solutions Software Effective Solutions/MedCana is a holding company…

Continue Reading

WednesdayOct 09, 2024 12:35 pm

CBDNewsBreaks – Software Effective Solutions Corp. (d/b/a MedCana) (SFWJ) Releases Report on Series of Acquisitions, Multiple Cannabis Licenses

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ), a leading global infrastructure holding company focused on the pharmaceutical-grade cannabis industry, is reporting on recent acquisitions and cannabis licenses associated with the acquisitions. According to the announcement, the new acquisitions and licenses, which will add $1.6 million to company assets for the third quarter, are designed to bolster the company's cannabis portfolio globally and solidify its position as a leading force in the cannabis sector. According to the announcement, the licenses include seven produce, process and sell CBD licenses; seven produce, process and sell THC licenses; seven fabrication of products containing…

Continue Reading

FridaySep 27, 2024 3:20 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Continue Reading

FridaySep 20, 2024 3:30 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

Continue Reading

FridaySep 13, 2024 3:27 pm

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently released its fiscal report for the third quarter of the 2024 financial year (“Q3, 2024”). “Of note was growth in cash and marketable securities from $1.5 million during the same period in the 2023 financial year to $8.5 million as of May 31, 2024. The company reduced certain R&D expenditures and experienced other savings,” reads a recent article. “Most importantly, however, were the program updates for initiatives it embarked on for 2024. A highlight of its projects has been its glucagon-like peptide-1 (‘GLP-1’) agonist research program. GLP-1, a class of drugs, has demonstrated an…

Continue Reading

ThursdaySep 12, 2024 12:05 pm

CBDNewsBreaks – Golden Triangle Ventures Inc. (GTVH) Announces Partnership to Boost Operational Capacity, Sustain Revenue Growth in Logistics Division

Golden Triangle Ventures (OTC: GTVH), a multifaceted consulting company, today announced a strategic partnership between LE Logistics, LLC, its wholly owned subsidiary, and West End Trucking, Inc. The partnership is expected to significantly boost the company’s asset base and operational capacity and set the stage for continued revenue growth and long-term success. Under the partnership, LE Logistics will manage and operate a fleet of 13 trucks and trailers under its own and West End’s licenses. Specifically, LE Logistics will handle all day-to-day logistics operations and create a robust system for fleet management, while West End will ensure compliance with all…

Continue Reading

ThursdaySep 05, 2024 11:16 am

CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced the appointment of Richard Christopher as the new CEO, effective August 31, 2024. Mr. Christopher is a recognized industry veteran with over three decades of experience in the medical device and pharmaceutical industries. He has domestic and international experience in leadership, operations, acquisitions/licensing, business development, strategic planning and capital markets. Mr. Christopher takes over from outgoing CEO, Chris Bunka, who has stepped aside from the role. Mr. Bunka remains as the Chairman of the Board of Directors and has been appointed Executive Strategic Advisor to the…

Continue Reading

CBDWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000